JHLT Open最新文献

{"title":"The length of the warm ischemic interval in lung donation after circulatory death does not impact post-transplantation outcomes","authors":"Amer Alzahrani MD ,&nbsp;Kentaro Noda PhD ,&nbsp;Ernest G. Chan MD ,&nbsp;John P. Ryan PhD ,&nbsp;Masashi Furukawa MD, PhD ,&nbsp;Pablo G. Sanchez MD, PhD","doi":"10.1016/j.jhlto.2025.100244","DOIUrl":"10.1016/j.jhlto.2025.100244","url":null,"abstract":"<div><h3>Introduction</h3><div>Transplantation of lungs obtained by donation after circulatory death (DCD) has increased the number of available organs. This study aims to determine how donor characteristics and current procurement processes (specifically, agonal and warm ischemic times) influence the outcomes experienced by the recipients of DCD lung transplants.</div></div><div><h3>Materials and Methods</h3><div>An analysis was conducted on United Network for Organ Sharing data collected from January 2018 to June 30, 2024, with a focus on adult recipients of double lung transplants with a DCD donor. Withdrawal-to-flush and agonal-to-flush times were divided into three non-overlapping intervals. Univariable comparisons were performed on donor and recipient characteristics and post-transplantation outcomes between intervals. Kaplan-Meier analyses were used to determine the impact of agonal and warm ischemic times on posttransplant survival.</div></div><div><h3>Results</h3><div>The median times for withdrawal-to-flush and agonal-to-flush were 28 and 25 minutes, respectively, with closely aligned intervals. Donors in the short agonal-to-flush category were generally older and tended to be female, with no other significant donor characteristics associated with the time intervals. There were no observed associations between agonal or warm ischemic times and post-transplant outcomes, including primary graft dysfunction, ventilator dependency, and acute rejection. Kaplan-Meier survival analysis revealed no significant differences in survival between the groups (p=0.47 for withdrawal-to-flush; p=0.57 for agonal-to-flush).</div></div><div><h3>Conclusions</h3><div>This study suggests that current variations in withdrawal-to-flush and agonal-to-flush times are not associated with DCD lung transplant outcomes. The findings underscore the need for expanding strategies to increase the utilization and availability of DCD lungs.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100244"},"PeriodicalIF":0.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-center perioperative management and 1-year heart transplantation outcomes for patients with adult congenital heart disease","authors":"Reice Robinson MD ,&nbsp;Samvel Gaboyan ,&nbsp;Laith Alshawabkeh MD ,&nbsp;Ryan Reeves MD ,&nbsp;Eugene Golts MD ,&nbsp;Victor Pretorius MBChB ,&nbsp;John Nigro MD ,&nbsp;Mark Kearns MD ,&nbsp;Howaida El-Said MD, PhD ,&nbsp;Matthew Carazo MD ,&nbsp;Kimberly Hong MD ,&nbsp;Eric Adler MD ,&nbsp;Paul J. Kim MD, MAS ,&nbsp;Amanda Topik NP ,&nbsp;Deborah Raleigh NP ,&nbsp;Angela Meier MD, PhD ,&nbsp;Sarah Ellis MD ,&nbsp;Ramon Sanchez MD ,&nbsp;Kamyar Afshar DO ,&nbsp;Aarya Kafi MD ,&nbsp;Marcus A. Urey MD","doi":"10.1016/j.jhlto.2025.100243","DOIUrl":"10.1016/j.jhlto.2025.100243","url":null,"abstract":"<div><h3>Background</h3><div>Additional data are needed to define the optimal listing strategy and peri-transplant management for adults with congenital heart disease (ACHD). In this study, we evaluated the perioperative management and 1-year outcomes for 30 patients who underwent orthotopic heart transplantation (OHT) for ACHD.</div></div><div><h3>Methods</h3><div>We conducted a single-center retrospective case series of all patients who received an OHT at our institution for ACHD from January 1, 2017 through June 30, 2024. Descriptive statistical analyses were used to illustrate the baseline characteristics, peri-transplant management, and 1-year outcomes of participants.</div></div><div><h3>Results</h3><div>Seventeen (56.7%) patients received a heart-only transplant, 4 (13.3%) had a heart-lung transplant, 8 (26.7%) had a heart-liver transplant, and 1 (3.3%) had a heart-liver-kidney transplant. Embolization of aortopulmonary and venous collateral vessels before transplantation was performed in 12 (80%) Fontan patients, with a median of 2 procedures per patient. Twenty-eight (93.3%, <em>n</em> = 30) patients were alive at 90 days, and 26 (92.9%, <em>n</em> = 28) were alive at 1 year.</div></div><div><h3>Conclusions</h3><div>This cohort of ACHD patients had a 92.9% 1-year survival rate, consistent with other high-volume centers in the United States. In this paper, we discuss our institutional practices that address barriers to transplant for ACHD patients, such as early referral for transplant, indications for listing, pretransplant embolization of collateral vessels, and multiorgan transplant.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100243"},"PeriodicalIF":0.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel pretransplant desensitization strategies in heart transplantation","authors":"Guillaume Coutance MD, PhD ,&nbsp;Anita S. Chong PhD ,&nbsp;Marlena V. Habal MD","doi":"10.1016/j.jhlto.2025.100242","DOIUrl":"10.1016/j.jhlto.2025.100242","url":null,"abstract":"<div><div>Allosensitization remains a major barrier in thoracic organ transplantation, limiting access to transplantation and increasing waitlist mortality and post-transplant morbidity. Desensitization protocols aimed at improving access to transplantation and mitigating the risk of early post-transplant rejection have been developed, but current strategies have limited efficacy, and new strategies are needed. After a synthetic description of the basics of alloimmune responses leading to the production of donor-specific antibodies, the potential of novel desensitization strategies, including anti-CD38 therapies, costimulation blockade, and interleukin-6 inhibition as pretransplant desensitization therapies, are discussed in detail, including the rationale for their use, results of preclinical and clinical studies, and potential practical clinical application. Complementary novel pharmacologic (individualization therapies, combination desensitization therapies, additional perioperative antibody-risk mitigation strategies) and nonpharmacologic strategies (individual risk stratification and combination of immunologic assays) are also presented. Finally, potential next-generation therapies (bispecific T-cell engager and chimeric antigen receptor T cells) and clinical outcomes of interest are briefly discussed. Overall, this review aims to provide recent data on this constantly evolving field, while keeping in mind the clinical applicability and providing practical aspects of the use of novel pretransplant desensitization therapies.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100242"},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of genetic recovery despite phenotypic recovery - are these the key to understanding remission vs recovery from heart failure? - Genetic analysis of a mouse model of recovery","authors":"Khush Patel MD, MS ,&nbsp;Muthu Kumar Krishnamoorthi PhD ,&nbsp;Linda W. Moore PhD ,&nbsp;Arvind Bhimaraj MD, MPH","doi":"10.1016/j.jhlto.2025.100236","DOIUrl":"10.1016/j.jhlto.2025.100236","url":null,"abstract":"<div><div>Heart failure (HF) remission involves the normalization of cardiac function but is accompanied by a risk of relapse. The key to achieving (complete) recovery may lie in identifying genes that remain persistently dysregulated despite phenotypic normalization. We used a mouse model of non-ischemic HF recovery to identify persistently dysregulated genes in phenotypically recovered myocardium compared to HF. RNA-seq data from male C57BL/6 mice that underwent HF induction followed by phenotypic recovery were analyzed. Differential expression analyses identified 18 persistently altered genes: 17 were upregulated, and 1 was downregulated. Notably, the only downregulated gene was the transferrin receptor gene (<em>Tfrc</em>), whereas transferrin (<em>Trf</em>) was upregulated, suggesting a role of ferroptosis pathways. Persistently dysregulated genes, especially those related to iron metabolism and ferroptosis, are potential therapeutic targets to sustain cardiac recovery from HF.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100236"},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of health literacy in lung transplant candidates","authors":"Jorge Vinales BS ,&nbsp;Rommel Sagana MD ,&nbsp;Kiran H. Lagisetty MD ,&nbsp;Corey Powell PhD ,&nbsp;Jeffrey Clay ADN ,&nbsp;Rebecca Hunt BSN ,&nbsp;Jennifer Shevket BSN ,&nbsp;Vikas Sood MSN ,&nbsp;Ashwin Kulkarni BS ,&nbsp;Krysta Walter PharmD","doi":"10.1016/j.jhlto.2025.100240","DOIUrl":"10.1016/j.jhlto.2025.100240","url":null,"abstract":"<div><div>Understanding health literacy is critical to making informed decisions in healthcare. To date, there are no studies regarding the landscape of health literacy in patients undergoing lung transplant evaluation. In this single center prospective pilot study, patients undergoing evaluation for lung transplantation participated in a pre-transplant education class followed by an educational assessment administered electronically. The Brief Health Literacy Screening Tool (BRIEF) was then electronically administered to assess health literacy among patients. Thirty patients participated. Most patients (77%) demonstrated adequate health literacy. The pre-transplant education assessment score and BRIEF survey scores correlated (R=0.43 [95% CI 0.06–0.70, P =0.025]). Inadequate/marginal health literacy was seen in 13% (2/16) of patients listed for transplant and 36% (5/14) of patients not listed for transplant (p=0.37).</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100240"},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HOPE in every breath and heartbeat: Understanding transplant eligibility, access barriers, and clinical outcomes in thoracic transplantation in persons with HIV","authors":"Patrick C.K. Tam ,&nbsp;Julia A. Messina ,&nbsp;Bin Ni ,&nbsp;Madeleine R. Heldman ,&nbsp;Julie M. Steinbrink ,&nbsp;John M. Reynolds ,&nbsp;Adam D. DeVore ,&nbsp;Arthur W. Baker ,&nbsp;Manuela Carugati ,&nbsp;Ilan S. Schwartz ,&nbsp;Cameron R. Wolfe","doi":"10.1016/j.jhlto.2025.100238","DOIUrl":"10.1016/j.jhlto.2025.100238","url":null,"abstract":"<div><h3>Background</h3><div>Persons with human immunodeficiency virus (PWH) are living longer, leading to increased end-organ disease from chronic illness. Organ transplantation improves survival in patients with end-organ disease yet remains a constrained resource due to limited access. We aimed to better understand barriers to transplantation for thoracic end-organ disease in PWH.</div></div><div><h3>Methods</h3><div>We performed a retrospective study of patients referred to our center for consideration of thoracic organ transplant and assessed the factors associated with transplant eligibility in candidates with human immunodeficiency virus (HIV). We also assessed clinical outcomes in PWH progressing to transplant.</div></div><div><h3>Results</h3><div>Over a 10-year period, 30 HIV-seropositive candidates and 10,905 HIV-seronegative candidates were referred to our center. Of candidates referred, 40% (12 of 30) of HIV-seropositive candidates were waitlisted compared to 20% (2,172 of 10,905) of HIV-seronegative candidates (<em>p</em> = 0.006). The median time from referral to waitlist activation in HIV-seropositive and HIV-seronegative candidates was similar (103 days vs 102 days, respectively; <em>p</em> = 0.92). Eight (27%) HIV-seropositive candidates underwent transplant compared to 1,962 (18%) HIV-seronegative candidates (<em>p</em> = 0.22). The median waitlist time in HIV-seropositive and HIV-seronegative candidates was similar (20 days vs 16 days, respectively; <em>p</em> = 0.98). Of the 8 HIV-seropositive transplant recipients, no recipient developed any HIV-associated complication, and 7 recipients (88%) survived beyond 1 year.</div></div><div><h3>Conclusions</h3><div>HIV-seropositive thoracic transplant candidates were more likely to be waitlisted compared to HIV-seronegative candidates. Progression to transplant and waitlist times were similar between candidates with and without HIV. Our study suggests that HIV alone was not a significant barrier to transplantation in PWH when referred and evaluated for thoracic organ transplantation.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100238"},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caregiver burden in lung transplantation: A review","authors":"Keerthana Sankar MD ,&nbsp;Anne Johnson LCSW ,&nbsp;Kathryn McRae LCSW ,&nbsp;Reinaldo Rampolla MD ,&nbsp;Nicholas A. Kolaitis MD, MAS","doi":"10.1016/j.jhlto.2025.100239","DOIUrl":"10.1016/j.jhlto.2025.100239","url":null,"abstract":"<div><div>Caregivers play a pivotal role in supporting patients undergoing lung transplant and often experience significant psychological, physical, and financial burdens. The current literature suggests that caregivers face heightened depression and anxiety in both the pre- and post-transplant periods. Caregivers of lung transplant patients may face unique challenges compared to other caregiver populations due to fears regarding pre- and post-transplant survival, lifestyle changes associated with post-transplant complications, and financial burden due to job loss and relocation. Caregiver well-being is linked to patient outcomes, with increased burden associated with higher post-transplant mortality. This review summarizes the symptoms associated with caregiver burden, assessment tools to evaluate caregiver strain, patient outcomes and social determinants of health as it relates to caregiver-patient relationships, and interventions to mitigate caregiver burden in the lung transplant population.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100239"},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacodynamics monitoring after lung transplantation","authors":"Manuel Lopez-Meseguer ,&nbsp;Marta Zapata-Ortega ,&nbsp;Cristina Berastegui Garcia ,&nbsp;Marta Andreu Casas ,&nbsp;Paula Barquero Dueñas ,&nbsp;Victor Monforte ,&nbsp;Carlos Bravo ,&nbsp;Susana Gomez-Olles ,&nbsp;Berta Saez-Gimenez ,&nbsp;Eva Revilla-Lopez","doi":"10.1016/j.jhlto.2025.100233","DOIUrl":"10.1016/j.jhlto.2025.100233","url":null,"abstract":"<div><div>Defining the optimal dosage of immunosuppressive drugs remains a significant challenge for solid organ transplant recipients, particularly for lung transplant recipients, who face an increased risk of infection. In these patients, it is crucial to carefully balance immunosuppression to ensure efficacy, prevent rejection, and minimize toxicity. Although the limitations of therapeutic drug monitoring have been widely discussed, pharmacodynamics monitoring has not reached the clinical practice. This review aims to evaluate the various methodologies available for monitoring the effects of immunosuppression in individual patients. While the initial focus was on directly assessing the impact of immunosuppressive treatments, we found limited evidence in this area. Instead, much of the available research is focused on predicting specific outcomes and indirectly assessing immunosuppression needs in lung transplant recipients. In this review, we provide an overview of the different methodologies that can be utilized to enhance the personalization of immunosuppressive therapy following lung transplantation. These include enzymatic monitoring, T-cell mediated functional assays, monitoring of lymphocyte subsets, gene expression profiling, and viral load measurements. Each of these approaches may contribute to a more tailored and effective immunosuppressive strategy for lung transplant recipients.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100233"},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing risk of postlung transplant hospitalizations for infection: An analysis of recent trends","authors":"Shi Nan Feng BSPH ,&nbsp;Armaan F. Akbar BS ,&nbsp;Alice L. Zhou MS ,&nbsp;Andrew Kalra BS ,&nbsp;Sean Agbor-Enoh MD, PhD ,&nbsp;Christian A. Merlo MD, MPH ,&nbsp;Errol L. Bush MD","doi":"10.1016/j.jhlto.2025.100231","DOIUrl":"10.1016/j.jhlto.2025.100231","url":null,"abstract":"<div><h3>Background</h3><div>Despite advancements in lung transplantation (LT), infection remains a major cause of morbidity and mortality following LT. We examined trends in hospitalizations for infection in the first year after LT.</div></div><div><h3>Methods</h3><div>We identified adult LT recipients in the United States (March 1, 2018-March 9, 2023) using the Organ Procurement and Transplantation Network database. We categorized transplants into 3 eras to account for the Composite Allocation Score allocation policy change and coronavirus disease 2019: March 2018 to March 2020, March 2020 to March 2022, and March 2022 to March 9, 2023. One-year post-LT survival was compared using Kaplan-Meier survival analysis and Cox proportional hazards regression. Hospitalizations for infection were compared using multivariable logistic regression, adjusted for era and donor and recipient characteristics.</div></div><div><h3>Results</h3><div>Of 12,388 LT recipients (median age = 62, male = 61.2%), hospitalization for infection in the first-year post transplant was 5.2% for patients transplanted from March 2018 to March 2020 (N = 5,031), 7.6% from March 2020 to March 2022 (N = 4,659), and 13.2% post-March 2022 (N = 3,640) (<em>p</em> &lt; 0.001). Compared to March 2018 to March 2020, patients transplanted from March 2020 to March 2022 (adjusted aoods ratio [aOR] = 1.50, 95% confidence interval [CI] = 1.26-1.79) and post-March 2022 (aOR = 2.89, 95% CI = 2.29-3.65) were more likely to be hospitalized for an infection. After adjustment, we found no significant difference in risk of death following LT for recipients transplanted between March 2020 and March 2022 (aHR = 1.09, 95% CI = 0.96-1.23, <em>p</em> = 0.175) compared to March 2018 and March 2020. Post-March 2022 risk of death was elevated (aHR = 1.21, 95% CI = 1.04, 1.40, <em>p</em> = 0.014).</div></div><div><h3>Conclusions</h3><div>Odds of hospitalization for infection in the first year after LT performed between March 2020 and March 2022 and post-March 2022 were 1.50 and 2.89 times as high, respectively, as LT performed between March 2018 and March 2020.</div></div><div><h3>IRB NUMBERS</h3><div>IRB00352819</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100231"},"PeriodicalIF":0.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of target temperature on effectiveness of myocardial preservation during hypothermic machine perfusion","authors":"Guilherme Mainardi Aguiar da Silva MD ,&nbsp;Mitchell J. Wagner ,&nbsp;Sanaz Hatami MD/PhD ,&nbsp;Parham Hassanzadeh ,&nbsp;Xiuhua Wang PhD ,&nbsp;Benjamin A. Adam MD ,&nbsp;Jayan Nagendran MD/ PhD ,&nbsp;Darren H. Freed MD/PhD","doi":"10.1016/j.jhlto.2025.100234","DOIUrl":"10.1016/j.jhlto.2025.100234","url":null,"abstract":"<div><h3>Background</h3><div>Ex-situ heart perfusion (ESHP) has been proposed as an optimal method for preserving donated hearts prior to transplantation. Hypothermic oxygenated perfusion (HOP) is a simple method from a device design perspective, with enhanced safety compared to normothermic perfusion in the event of device failure. However, the optimal temperature for cardiac HOP has yet to be determined. We evaluated the effectiveness of 12-hour HOP using University of Wisconsin Machine Perfusion Solution (UWMPS) in different temperatures compared to static cold storage (SCS) for 6 hours followed by simulated transplantation. Additionally, we sought to determine the impact of oxygen supplementation in hypothermic ESHP in the heart function preservation.</div></div><div><h3>Methods</h3><div>Hearts were procured from Yorkshire pigs (<em>n</em> <!-->=<!--> <!-->35) randomized into 3 preservation therapies: 6<!--> <!-->hours-SCS; 12<!--> <!-->hours-HOP and 12 hours hypothermic non-oxygenated perfusion (HNOP-without oxygen supplementation). For either HOP or HNOP groups, 3 temperatures were tested (5°C; 10°C; 15°C). After the preservation period, hearts had their function assessed in a normothermic perfusion machine capable of working mode, simulating transplantation.</div></div><div><h3>Results</h3><div>All perfusion parameters were stable throughout (mean<!--> <!-->±<!--> <!-->SD): aortic flow 65<!--> <!-->±<!--> <!-->5.57 ml/min, aortic pressure: 11.51<!--> <!-->±<!--> <!-->3.17 mm<!--> <!-->Hg. All HOP hearts presented a better cardiac index than SCS (<em>p</em> <!-->&lt;<!--> <!-->0.05). The HNOP hearts presented similar cardiac function results compared to SCS.</div></div><div><h3>Conclusions</h3><div>HOP for 12 hours had better heart function preservation than SCS for 6 hours. Even HNOP had similar results compared to SCS. Greater edema formation in ESHP hearts did not affect heart function. Hypothermic ESHP safely enhances function preservation compared to SCS.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100234"},"PeriodicalIF":0.0,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}